Pembrolizumab for recurrent head and neck squamous cell carcinoma (HNSCC): Post hoc analyses of treatment options from the phase III KEYNOTE-040 trial
Year: 2018
Type: article
Abstract: Background: In the phase 3, randomized, open-label KEYNOTE-040 study (NCT02252042), pembrolizumab (pembro), compared with standard of care (SOC), prolonged survival in patients (pts) with recurrent and/or metastatic HNSCC that progressed during or after platinum-based therapy. Post hoc analyses were conducted to evaluate pembro vs SOC by (1) each of 3 SOC choices, (2) prior cetuximab, and (3) second PFS (PFS2; time from randomization to disease progression after initiation of new anticancer therapy).
Source: Annals of Oncology
Institutions: Inserm, Université de Versailles Saint-Quentin-en-Yvelines, Institut Curie, UC San Diego Health System, Moores Cancer Center, Royal Marsden NHS Foundation Trust, Institute of Cancer Research, NIHR Biomedical Research Centre at The Royal Marsden and the ICR, IPO Porto, University of Milan, Fondazione IRCCS Istituto Nazionale dei Tumori, Samsung Medical Center, Hospital Universitario Ramón y Cajal, Cliniques Universitaires Saint-Luc, UCLouvain, University Hospital of Geneva, Fox Chase Cancer Center, Johns Hopkins University, Johns Hopkins Medicine, Sidney Kimmel Comprehensive Cancer Center, Yale Cancer Center, Yale University, Merck & Co., Inc., Rahway, NJ, USA (United States), Centre Hospitalier de l’Université de Montréal, Université de Montréal
Language: English
Topic: Head and Neck Cancer Studies
Subfield: Otorhinolaryngology
Field: Medicine
Domain: Health Sciences
Open Access status: hybrid
Estimated APC paid: $5,080
OpenAlex ID: W2897256455